Benchmark analyst Aydin Huseynov said his comparison of the SARS-CoV2 antibody data reported by Eli Lilly (LLY) to the antibody data of Regeneron (REGN) leads him to conclude that Regeneron’s data is “much more granular and convincing.” Both Eli Lilly and Regeneron antibodies can be eventually authorized by the FDA, said Huseynov, although he suspects that the data for hospitalized patients is “not as convincing” for either given that its likely that group would include a high proportion of seropositive severe SARS-CoV2 patients. He maintains a Hold rating on Regeneron as he awaits clinically meaningful data for hospitalized patients.
In a statement issued last night, Regeneron said: “Subsequent to our discussions with regulatory authorities, we have submitted a request to the U.S. Food and Drug Administration for an Emergency Use Authorization, or EUA, for our REGN-COV2 investigational antibody combination for COVID-19. Under our agreement with the U.S. government for the initial doses of REGN-COV2, if an EUA is granted the government has committed to making these doses available to the American people at no cost and would be responsible for their distribution. At this time, there are doses available
For approximately 50,000 patients, and we expect to have doses available for 300,000 patients in total within the next few months.” Source: https://investor.regeneron.com/static-files/6feab76b-176d-402d-bf30-d40462e68b7b
U.S. infectious diseases expert Dr. Anthony Fauci said that President Donald Trump’s health was likely aided by an experimental therapy made by Regeneron, in which he received antibodies to combat COVID-19, Reuters’ Caroline Hunter reports. “There is a reasonably good chance that in fact it made him much better,” Fauci said in an interview on MSNBC. Fauci added that the coronavirus pandemic is much more serious than the seasonal flu, Hunter notes. Source: https://www.reuters.com/article/us-health-coronavirus-fauci/fauci-says-reasonably-good-chance-regeneron-antibody-therapy-helped-trump-idUSKBN26T30K
President Trump is urging regulators to approve emergency use authorizations for Regeneron’s and Eli Lilly’s antibody treatments. CNBC’s Meg Tirrell joins “Squawk Box” with the latest details on the developing story.